In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose
- PMID: 33646836
- DOI: 10.7326/ACPJ202103160-028
In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose
Abstract
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403-16. 33378609.
Comment on
-
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30. N Engl J Med. 2021. PMID: 33378609 Free PMC article. Clinical Trial.
Similar articles
-
The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.Ann Intern Med. 2021 Feb;174(2):JC15. doi: 10.7326/ACPJ202102160-015. Epub 2021 Feb 2. Ann Intern Med. 2021. PMID: 33524290
-
The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d.Ann Intern Med. 2021 Jul;174(7):JC75. doi: 10.7326/ACPJ202107200-075. Epub 2021 Jul 6. Ann Intern Med. 2021. PMID: 34224270
-
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877. Eur Rev Med Pharmacol Sci. 2021. PMID: 33629336 Review.
-
The Novavax vaccine had 90% efficacy against COVID-19 ≥7 d after the second dose.Ann Intern Med. 2021 Nov;174(11):JC124. doi: 10.7326/ACPJ202111160-124. Epub 2021 Nov 2. Ann Intern Med. 2021. PMID: 34724399
-
COVID-19 Vaccines: Current Status and Implication for Use in Indonesia.Acta Med Indones. 2020 Oct;52(4):388-412. Acta Med Indones. 2020. PMID: 33377885 Review.
Cited by
-
Kinetics of adaptive immune responses after administering mRNA-Based COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infections.BMC Infect Dis. 2023 Oct 27;23(1):732. doi: 10.1186/s12879-023-08728-5. BMC Infect Dis. 2023. PMID: 37891503 Free PMC article.
-
Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment.Int J Nanomedicine. 2021 Dec 16;16:8141-8158. doi: 10.2147/IJN.S332385. eCollection 2021. Int J Nanomedicine. 2021. PMID: 34949922 Free PMC article. Review.
-
Immune Thrombocytopenia Relapse in Patients Who Received mRNA COVID-19 Vaccines.J Blood Med. 2023 Apr 14;14:295-302. doi: 10.2147/JBM.S396026. eCollection 2023. J Blood Med. 2023. PMID: 37082002 Free PMC article.
-
SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies.J Allergy Clin Immunol Glob. 2023 Jun 25;2(4):100129. doi: 10.1016/j.jacig.2023.100129. eCollection 2023 Nov. J Allergy Clin Immunol Glob. 2023. PMID: 37781659 Free PMC article.
-
Proposals to Accelerate Novel Vaccine Development for Children.Pediatrics. 2021 Oct 22;149(1):e2021054593. doi: 10.1542/peds.2021-054593. Online ahead of print. Pediatrics. 2021. PMID: 34686571 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous